Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study

被引：0
|
作者：
Sexton, Daniel J. [1 ]
Brown, Nancy J. [2 ]
Lumry, William R. [3 ]
Gower, Richard G. [4 ]
Hao, James [1 ]
Lu, Peng [1 ]
Zafra, Heidi T. V. [5 ]
机构：
[1] Shire, Lexington, MA USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] AARA Res Ctr, Dallas, TX USA
[4] Marycliff Clin Res, Spokane, WA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2019年 / 143卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
136
引用
收藏
页码：AB46 / AB46
页数：1
相关论文
共 50 条
  • [1] Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study
    Schmaier, Alvin H.
    Bauer, Kenneth A.
    Cicardi, Marco
    Hebert, Jacques
    Johnston, Douglas T.
    Busse, Paula J.
    Paes, Kim
    Sexton, Daniel J.
    Kenniston, Jon
    Nurse, Christina
    Zaragoza, Rafael H.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB42 - AB42
  • [2] LANADELUMAB SAFETY AND IMMUNOGENICITY: RESULTS FROM THE PHASE 3 HELP STUDY
    Johnston, D.
    Banerji, A.
    Riedl, M.
    Zuraw, B.
    Lumry, W.
    Bernstein, J.
    Li, H.
    Lu, P.
    Hao, J.
    Gower, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S36 - S36
  • [3] Efficacy of lanadelumab is durable over time: Findings from the HELP Study and HELP OLE
    Kiani-Alikhan, S.
    Riedl, M.
    Bernstein, J. A.
    Anderson, J.
    Tachdjian, R.
    Lu, P.
    Ren, H.
    Aygoeren-Puersuen, E.
    ALLERGY, 2020, 75 : 59 - 59
  • [4] LANADELUMAB FOR PREVENTION OF ATTACKS IN HEREDITARY ANGIOEDEMA: RESULTS FROM THE PHASE 3 HELP STUDY
    Banerji, A.
    Riedl, M.
    Bernstein, J.
    Cicardi, M.
    Longhurst, H.
    Zuraw, B.
    Maurer, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S5 - S5
  • [5] Lanadelumab for prevention of attacks in hereditary angioedema: results from the Phase 3 HELP Study
    Banerji, A.
    Riedl, M. A.
    Bernstein, J. A.
    Cicardi, M.
    Longhurst, H. J.
    Zuraw, B. L.
    Bruelle, J.
    Maurer, M.
    SWISS MEDICAL WEEKLY, 2018, 148 : 28S - 29S
  • [6] Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study
    Cicardi, M.
    Shennak, M.
    Zaragoza-Urdaz, R. H.
    Wang, Y.
    Lu, P.
    ALLERGY, 2018, 73 : 722 - 722
  • [7] Lanadelumab prophylaxis reduces breakthrough hereditary angioedema attacks and the need for rescue medication: Exploratory findings from the phase 3 HELP study
    Cicardi, M.
    Maurer, M.
    Longhurst, H. J.
    Johnston, D. T.
    Li, H. H.
    Nurse, C.
    Lu, P.
    Busse, P. J.
    ALLERGY, 2019, 74 : 212 - 212
  • [8] Subgroup Analyses From the Phase 3 HELP Study of Lanadelumab for the Prevention of Hereditary Angioedema Attacks
    Banerji, Aleena
    Manning, Michael E.
    Martinez-Saguer, Inmaculada
    Schwartz, Lawrence B.
    Smith, Andrew M.
    Yang, William H.
    Lu, Peng
    Hao, James
    Zuraw, Bruce L.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB43 - AB43
  • [9] High responder rates in lanadelumab-treated patients in the phase 3 HELP study
    Maurer, M.
    Davis-Lorton, M.
    Schranz, J.
    Hao, J.
    Busse, P. J.
    ALLERGY, 2018, 73 : 289 - 290
  • [10] Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies
    Craig, Timothy
    Zaragoza-Urdaz, Rafael
    Anderson, John
    Li, Huamin
    Paes, Kim
    Ren, Hong
    Juethner, Salome
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB21 - AB21
12345